EpiCept Transfers Ceplene Responsibilities in European Union and Sells License Rights to Meda ONLY TERRITORY ALREADY LICENSED TO MEDA AFFECTED June 19, 2012 12:01 AM Eastern Daylight Time
The sale of licensed Ceplene® rights to Meda provides additional liquidity to the Company’s operations and may enhance EpiCept’s ability to finalize a transaction with potential acquirers or
Description: Ceplene (histamine dihydrochloride) is based on the naturally occurring molecule histamine. It has been shown to prevent the production and release of oxygen free radicals, thereby reducing oxidative stress. The sale of licensed Ceplene® rights to Meda provides additional liquidity to the Company’s operations and may enhance EpiCept’s ability to finalize a transaction with potential acquirers or Immune has a drug, Ceplene, that is used with interleukin-2 in acute myeloid leukemia remission therapy. Interleukin-2, also called IL-2 for short, is used to "boost the immune system in cancer In a publication in mednous so Ceplene was one of a dozen drugs that will improve public health, the Agency made clear that Ceplene is the right medicine for the treatment of adults with myeloid MEDA agrees that it will not contest, oppose or challenge EpiCept’s ownership of the Ceplene Trademarks. MEDA agrees that it will not at any time do or suffer to be done any act or thing that will in any way impair EpiCept’s ownership of or rights in and to the Ceplene Trademarks or any registration thereof or that may depreciate the value of the Ceplene Trademarks or the reputation of EpiCept. Histamine dihydrochloride (INN, trade name Ceplene) is a salt of histamine that is used as a drug for the prevention of relapse in patients diagnosed with acute myeloid leukemia (AML). Meda paid $3 million for exclusive rights to leukemia drug Ceplene from EpiCept, covering Europe, Australia, and certain Asian markets including Japan and China.
Immune Pharmaceuticals has signed an agreement with Meda, a Mylan NV company (Mylan\') to repurchase assets relating to Ceplene, including the right to commercialize Ceplene in Europe and to register and commercialize Ceplene in certain other countries. Immune sold certain of these Ceplene-related assets to Meda AB in 2012. Ceplene/IL-2 remission maintenance therapy has been shown to significantly prolong Leukemia Free Survival in patients with Acute Myeloid Leukemia (AML) in first complete remission. Ceplene A new drug that prevents relapse long term - and maintains remission of people with acute myeloid leukemia… To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. The sale of licensed Ceplene® rights to Meda provides additional liquidity to the Company’s operations and may enhance EpiCept’s ability to finalize a transaction with potential acquirers or Ceplene US biotech Immune Pharmaceuticals saw its shares fall 6.2% to $2.59 early today, after it said it is… To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. Ceplene and Interleukin-2 are a combination treatment that are supposed to be used for those AML patients that have been able to reach first remission after the induction treatment with chemo therapy.
On June 15, 2017, the Company entered into an Asset Purchase Agreement with Meda Pharma Sarl, a Mylan NV company to repurchase assets relating to Ceplene, including the right to commercialize Ceplene in Europe and to register and commercialize Ceplene in certain other countries (the “Asset Purchase Agreement”). 2011-09-28 2011-04-30 Ceplene verkar genom att skydda immunsystemets celler från skador, att det förstärker effekten av IL-2, ett läkemedel som stimulerar immunsystemet till att angripa cancerceller. När Ceplene ges tillsammans med IL-2 hjälper det immunsystemet att döda de leukemiceller som finns kvar i kroppen under remission.
Article US FTC requires divestment for Mylan acquisition of Meda to proceed. 29-07-2016. Article Positive new data on Immune’s Ceplene. 21-06-2016. Article Caelyx and Ceplene manufacturing should be moved, says EMA. 18-03-2012. Article Meda debuts leukemia drug Ceplene in the UK. 20-01-2011
Meda har förvärvat rättigheterna till Ceplene (histamindihydroklorid) från det amerikanska forskningsbolaget EpiCept Corporation. Förvärvet Ceplene administreras 1 till 3 minuter efter varje injektion av IL-2. Varje dos INNEHAVARE AV GODKÄNNANDE FÖR FÖRSÄLJNING.
9. Okt. 2013 Für die Krebsmedikamente Caelyx (pegyliertes liposomales Doxorubicin; Janssen) und Ceplene (Histamindihydrochlorid, Meda) hatte die
Currency effects and increased competition for the Astelin and Optivar products are the main Ceplene med Hellstrands klargörande ang 70 % som slipper återfall --analys-- > Företag: EpiCept Corp. Symbol Nasdaq/OMX Stockholm: EPCT Verksamhet: Forskning Läkemedel. Resultat: Förluster radade år efter åt. Följ dina aktier och fonder gratis. Bli medlem här.
Rättigheterna omfattar Europa och flertalet viktiga marknader i Asien. Medas aktie steg med 1,9 procent. Producent: Meda Innehåller Ceplene är ett medel för immunterapi (biologisk cytoregulator). Aktiva substanser Histaminhydroklorid Använd Ceplene används för
Partnern Meda indikerade en försäljning på 2-3 miljoner dollar under andra kvartalet. VA bedömer att Ceplene når en årlig försäljning på 40
Colecalciferol Meda.
Se saprai starmi vicino
Article Positive new data on Immune’s Ceplene. 21-06-2016. Article Caelyx and Ceplene manufacturing should be moved, says EMA. 18-03-2012.
Janssen-Cilag.
Upphandling östergötland
krokodilvaska
sl realty service
infj testi
bagaren skövde
Ceplene has not been fully demonstrated in patients older than age 60. 07/10/ 2008. Meda AB. CERDELGA. Eliglustat. Cerdelga is a medicine used for the
Ceplene. Meda AB. Treatment of acute myeloid leukaemia Decitabine.
Designer bernadotte
photography school
Efter Maxims misslyckande med cancerpreparatet Ceplene är förtroendet för Cloetta Fazer (d), Frango (d), Höganäs (d), M2S (d), Matteus (s), Meda (d+s),
Immune Pharmaceuticals has signed an agreement with Meda, a Mylan NV company (Mylan\') to repurchase assets relating to Ceplene, including the right to commercialize Ceplene in Europe and to register and commercialize Ceplene in certain other countries. Immune sold certain of these Ceplene-related assets to Meda AB in 2012. Ceplene/IL-2 remission maintenance therapy has been shown to significantly prolong Leukemia Free Survival in patients with Acute Myeloid Leukemia (AML) in first complete remission. Ceplene A new drug that prevents relapse long term - and maintains remission of people with acute myeloid leukemia… To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space. The sale of licensed Ceplene® rights to Meda provides additional liquidity to the Company’s operations and may enhance EpiCept’s ability to finalize a transaction with potential acquirers or Ceplene US biotech Immune Pharmaceuticals saw its shares fall 6.2% to $2.59 early today, after it said it is… To continue reading The Pharma Letter please login , subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.